Status:
COMPLETED
An Atlas of Airways at a Single Cell Level in Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis and Controls
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Pulmonary Disease, Chronic Obstructive
Interstitial Pulmonary Fibrosis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The increasing incidence of chronic respiratory disease is a public health problem that affects hundreds of thousands of people worldwide at all ages. Directly exposed to atmospheric airborne contamin...
Eligibility Criteria
Inclusion
- Absence of acute pathology
- Absence of symptom evoking an evolutionary pathology
- For healthy volunteers :
- Non-smoker (active or passive) or ex-smoker of less than 5 packet-years and quit for more than 10 years.
- Absence of known significant chronic pathology
- Normal Respiratory Function Test (RFT)
- Woman of childbearing age using an effective method of contraception
- For COPD patients :
- Diagnosis of COPD based on dyspnea, chronic cough or sputum production, a history of recurrent lower respiratory tract infections and/or a history of exposure to risk factors for the disease associated with spirometry that demonstrates a post-bronchodilator FEV1/FVC ratio \< 0.70 and lack of reversibility.
- Stage GOLD 1 (post-bronchodilator FEV1 ≥ 80% theoretical) or 2 (post-bronchodilator FEV1 between 50 and less than 80% theoretical) or 3 (post-bronchodilator FEV1 between 30 and less than 50% theoretical) For IPF patients
- Diagnosis of idiopathic pulmonary fibrosis made less than 5 years ago on the basis of scannographic and/or histological criteria and validated at a consultation meeting on interstitial pathology according to the ATS/ERS/JRS/ALAT 2018 recommendations.
Exclusion
- Recent rhino-bronchial infection (\< 6 weeks)
- Subjects on antiplatelet or other anticoagulant medication at risk of bleeding during sampling.
- Subjects with a history of clinically significant vaginal discomfort (i.e., recurrent or unconsciousness, etc.)
- History of allergy or intolerance to xylocaine and/or propofol
- History of significant epistaxis (i.e. recurrent epistaxis of any quantity or at least one severe epistaxis)
- Subject at risk of difficult intubation according to the criteria of the 2006 FSSR expert conference\*.
- Pregnant (a urine test will be performed for all women of childbearing age) or breastfeeding woman
- For patients :
- Long-term systemic corticosteroid therapy regardless of the reason for the prescription.
- Systemic corticosteroid therapy within the previous 3 months
- Patient on long-term oxygen therapy
- Chronic cardiovascular, neuro-psychic, metabolic pathology in progress, clinically significant or uncontrolled in the last 6 months
- Other associated chronic respiratory pathology (COPD, asbestosis, bronchiectasis ...)
Key Trial Info
Start Date :
November 18 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 18 2024
Estimated Enrollment :
71 Patients enrolled
Trial Details
Trial ID
NCT04529993
Start Date
November 18 2020
End Date
November 18 2024
Last Update
March 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, France, 06003